Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    ISSN: 1435-5922
    Keywords: hepatocellular carcinoma (HCC) ; arterial infusion chemotherapy ; reservoir ; portal vein tumor thrombosis ; Child's classification
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We performed repeated arterial infusion chemotherapy (RAIC) in 114 advanced hepatocellular carcinoma (HCC) patients, using a subcutaneous reservoir implanted under ultrasonic guidance. In 60 patients, this was the initial therapy for the primary tumor and the other 54 patients being treated for recurrent tumor. One hundred and seventy-one patients with advanced HCC who had been treated by transcatheter arterial emblization (TAE) or single bolus arterial infusion chemotherapy before RAIC was available served as historical controls. In 97 patients, anticancer agents (4′-epidoxorubicin or acurarubicin) and Lipiodol emulsion were used, and in 17, anticancer agents alone were given. The response rates were 39.2% in the Lipiodol group and 17.6% in the non-Lipiodol group. The dose of Lipiodol and the degree of liver invasion were the most important factors influencing the response rate. The 1-, 2-, and 3-year survival rates were 55.0%, 30.9%, and 21.2%, respectively. The long-termsurvival was compared in relation to Child's classification and the presence or absence of portal vein tumor thrombosis (PVTT). In non-PVTT patients, the results of initial therapy and therapy for recurrence were similar, but recurrent Child's C patients showed a poorer prognosis. In PVTT patients, initial therapy had a better prognosis than treatment for recurrence, but initial Child's C patients had a poor long-termprognosis. During the observation period, no severe complications were encountered, but in Child's C patients, hepatic function sometimes deteriorated. Compared with the results in the 171 controls, RAIC was more useful for advanced HCC as initial therapy, and it was also beneficial for the treatment of recurrence after TAE.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-2323
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Résumé Depuis l'introduction des modalités d'imagerie telles que l'échographie, la tomodensitométrie et la résonance magnétique nucléaire pour le diagnostic de carcinome hépaticellulaire (CHC), le dépistage est devenu plus fiable. Auparavant, la plupart des CHC étaient diagnostiqués lorsqu'ils atteignaient 5 cm de diamètre. Actuellement, on détecte des cancers de moins de 2 cm de diamètre et, par conséquent, la fréquence des patients chez qui on découvre un CHC a augmenté. Selon les chiffres des quatre dernières années dans notre hôpital, 42.1% des 240 patients ayant un CHC avaient une tumeur de moins de 2 cm de diamètre, 42.1% avaient une tumeur entre 2 à 5 cm de diamètre et 15.8% avaient une tumeur de plus de 5 cm de diamètre. Presque 90% des patients avec une tumeur de moins de 2 cm de diamètre avaient également une cirrhose, et il est bien connu que chez les patients ayant cette association, le CHC a une tendance à récidiver peu de temps après leur résection. Dans le traitement des CHC associé à une cirrhose, de nombreuses modalités thérapeutiques telles que l'embolisation artérielle par cathéter, la radiothérapie, l'alcoolisation par voie percutanée et la chimiothérapie par voie artérielle sont actuellement employées avec des résultats satisfaisants. Il existe, cependant, des limitations quant à leur résultats essentiellement en raison de l'importance de l'insuffisance hépatocellulaire d'une part et directement en rapport avec la taille de la tumeur d'autre part. Toutes ces modalités ne devraient pas être efficaces contre le cancer, mais aussi ne provoquaient pas de lésions supplémentaires surtout lorsqu'on est amené à les répéter.
    Notes: Abstract Modern imaging modalities have allowed us to make reliable diagnosis of hepatocellular carcinoma (HCC). Most of HCCs are associated with liver cirrhosis in varying stages of severity and often accompanied by new occurrences of HCC after treatment. Now, newly developed nonsurgical therapeutic modalities are used extensively and achieve good results in terms of anti-tumor effects as well as post-treatment survival.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We conducted a prospective randomized trial to evaluate the efficacy of Lipiodol in intrahepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma (HCC). A total of 38 patients with unresectable HCCs and underlying cirrhosis were entered in this trial, and 36 of them were evaluable. Every 4 weeks, 17 patients received 70 mg of 4′-epidoxorubicin (epirubicin) alone (group A), whereas 19 patients received a Lipiodol emulsion containing the same dose of epirubicin (group B) through the hepatic artery. A tumor response (CR+PR) was observed in 12% of group A patients and in 42% of group B patients. The group B patients showed a significantly higher response rate than the group A patients. There was a tendency for an increased duration of survival (P=0.09) in the group B patients. These results suggested that the infusion of the Lipiodol emulsion with epirubicin was more effective than epirubicin alone for the treatment of these patients with HCC.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...